DoD and SPORE Ovarian Cancer Omics Consortium - DSOCOC

This research initiative represents an unprecedented collaboration of leading ovarian cancer investigators to capitalize on recent discoveries about the origin of ovarian cancer and apply state-of-the-art omics technologies to discover biomarkers that could lead to an early detection test for ovarian cancer.

Funded by a pilot grant from the U.S. Department of Defense (DoD) investigators from the three ovarian cancer SPOREs (Roswell Park Comprehensive Cancer Center-University of Pittsburgh Cancer Institute, Mayo Clinic, and M.D. Anderson Cancer Institute) and the DoD’s Gynecologic Cancer Center of Excellence (GYN-COE) created a consortium dedicated to the discovery of cost-effective biomarkers for early detection of ovarian cancer — the DoD and SPORE Ovarian Cancer Omics Consortium (DSOCOC).

Co-Principal Investigators 

  • Kunle Odunsi, MD, PhD, FRCOG, FACOG, Chair of the Department of Gynecologic Oncology, Executive Director of the Center for Immunotherapy at Roswell Park
  • Larry Maxwell, MD, Chair of Obstetrics and Gynecology at Inova Fairfax Women’s Hospital, co-PI for the Department of Defense (DoD) Gynecologic Cancer Center of Excellence (GYN-COE)
I don’t believe there has ever been such a united effort in medical science among researchers from both government and academic research organizations. This project will rely on expertise and resources that could only be realized through such a cooperative and collaborative effort. We’re able to set our sights much higher by working together and creating a force multiplying synergy.
Dr. Larry Maxwell 2020
Larry Maxwell, MD
Chair of Obstetrics and Gynecology
Inova Fairfax Women’s Hospital

The goal of the consortium is to develop the infrastructure for a multi-institutional research effort leveraging new and existing biospecimens, datasets, and multidisciplinary expertise in omics analyses to study the origin of high grade serous ovarian cancer (HGSOC), and use the knowledge to develop novel strategies for early detection and screening. Building on recent omics discoveries about the origins of ovarian cancers, the researchers are aiming to gather and interrogate biospecimens and clinical data to discover and validate biomarkers and inform early detection of and screening for serous tubal intraepithelial carcinoma (STIC) and ovarian cancer.

Collaboration Opportunities

Our goal is to gather as many STIC biospecimens as possible, from institutions across the country, for our investigation — but we need a large network of collaborators to succeed. Learn how to be a part of our effort to find an early detection test for ovarian cancer. 

Read More

Meet the Team

An unprecedented collaboration of leading ovarian cancer investigators that could lead to an early detection test for ovarian cancer.

Read More

Publications

Read the publications that have informed and inspired this work.

Read More